Bryan E. Smith - 21 Nov 2024 Form 4 Insider Report for Eledon Pharmaceuticals, Inc. (ELDN)

Reporting relationship: General Counsel, Corporate Sec
Issuer ticker: ELDN
Reported as of: 21 Nov 2024
Net transaction value: $0
SEC form: 4
Accepted by SEC: 22 Nov 2024, 17:00:06 UTC
Prior SEC filing: 14 Jun 2024
Next SEC filing: 13 Jan 2025
Source filing: View source filing
Reporting owner signature: /s/ Paul Little, as attorney-in-fact for Bryan Smith

Key filing fact

Bryan E. Smith filed Form 4 for Eledon Pharmaceuticals, Inc. (ELDN) on 22 Nov 2024.

Key facts

This page summarizes Bryan E. Smith's Form 4 filing for Eledon Pharmaceuticals, Inc. (ELDN).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 22 Nov 2024, 17:00.

Change

Previous filing in this sequence was filed on 14 Jun 2024.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ELDN transaction Derivative

Stock Option (right to buy)

Award

Transaction value: $0
Shares: +474,350
Change %
Price: $0.000000
Shares after: 474,350
Date: 21 Nov 2024
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 474,350
Exercise price: $2.30
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

This transaction represents the attainment of the performance conditions applicable to an option award subject to both performance-based and time-based vesting criteria granted to the reporting person on May 1, 2023. The option was determined to satisfy the performance-based vesting criteria with respect to 474,350 shares of underlying Common Stock on November 21, 2024 and time-based vesting criteria with respect to 177,881 shares of underlying Common Stock on November 1, 2024. The option will satisfy the time-based vesting criteria with respect to the 296,469 remaining shares of Common Stock underlying the option in substantially equal quarterly installments over a three-year period ending May 1, 2027.